SHR-4394 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-4394-101: Phase I clinical study of safety, tolerability, pharmacokinetics and efficacy of SHR-4394 for injection in patients with prostate cancer (ChiCTR) - P1 | N=180 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; Jiangsu Hengrui Pharmaceutical Co., LTD

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

SHR-4394-101: A Study of SHR-4394 Injection in Subjects With Prostate Cancer (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of SHR-4394 Injection in Subjects With Prostate Cancer (clinicaltrials.gov) - P1 | N=240 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Hengrui Medicine’s innovative drug SHR-4394 is approved for clinical trials for advanced prostate cancer [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Hengrui Medicine and its subsidiary Shanghai Hengrui Medicine Co., Ltd. received the 'Notice of Approval for Drug Clinical Trial' approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of SHR-4394 injection for advanced prostate cancer."

New trial • Prostate Cancer